Abstract:The effect and potential molecular mechanisms of berberine on gluconeogenesis in skeletal muscles and adipose tissues were investigated. After adaptive feeding for one week, 8 rats were randomly selected as the normal group and fed on a standard diet. The remaining 32 rats were fed on a high-fat diet and given an intravenous injection of streptozotocin (STZ) for 2 weeks to induce the diabetic models. The diabetic rat models were confirmed by oral glucose tolerance test (OGTT) and randomly divided into 4 groups (n=8 each), which were all fed on a high-fat diet. Berberine (3 g/kg per day) or metformin (183 mg/kg per day) was intragastrically administered to the diabetic rats for 12 weeks, serving as berberine group and metformin group respectively. 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside [AICAR, an agonist of AMP-activated protein kinase (AMPK), 0.5 mg/kg per day] was subcutaneously injected to the diabetic rats for 12 weeks, serving as AICAR group. The remaining 8 diabetic rats served as the model group, which was given a 0.5% carboxyl methylcellulose solution by oral gavage. Fasting serum insulin (FINS), OGTT as well as lipid parameters were tested by commercial kit. The protein levels of liver kinase B1 (LKB1), AMPK, phosphorylated AMP-activated protein kinase (p-AMPK), transducer of regulated CREB activity 2 (TORC2), phosphorylated transducer of regulated CREB activity 2 (p-TORC2), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in skeletal muscles and adipose tissues were examined by Western blotting. The results showed that berberine significantly decreased the body weight, plasma glucose, insulin levels, and homeostatic model assessment for insulin resistance (HOMA-IR) of diabetic rats compared with those in the model group. Meanwhile, the serum total triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels were markedly decreased and high-density lipoprotein cholesterol (HDL-C) level was significantly increased after the treatment with berberine. In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues. Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group. It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.

Mitochondrial Inhibitor As a New Class of Insulin Sensitizer

Akt Activation: A Potential Strategy to Ameliorate Insulin Resistance.

Akt activation: A potential strategy to ameliorate insulin resistance

AMPK acts as a new target for the treatment of type 2 diabetes

Targeting Mitochondrial Biogenesis for Preventing and Treating Insulin Resistance in Diabetes and Obesity: Hope from Natural Mitochondrial Nutrients

A spotlight on underlying the mechanism of AMPK in diabetes complications

Berberine improves glucose metabolism through induction of glycolysis

Mechanisms of Insulin Resistance in Obesity

Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation.

Effects and mechanisms of berberine in diabetes treatment

The Role of AMPK in Regulation of the Insulin Signal Transduction Pathway

Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications

Design, Synthesis and Biological Evaluation of 4,7,12,12A-Tetrahydro-5h-thieno[3',2':3,4]Pyrido[1,2-b]isoquinolines As Novel Adenosine 5'-Monophosphate-activated Protein Kinase (AMPK) Indirect Activators for the Treatment of Type 2 Diabetes.

AMPK Activators As Novel Therapeutics for Type 2 Diabetes

AMPD1: a Novel Therapeutic Target for Reversing Insulin Resistance

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

Berberine promotes glucose consumption independently of AMP-activated protein kinase activation

Natural activators of AMPK signaling: potential role in the management of type-2 diabetes

Berberine acutely inhibits insulin secretion from β-cells through 3′,5′-cyclic adenosine 5′-monophosphate signaling pathway

The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus

Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway